Goldman Sachs anticipates double-digit earnings growth for Teva Pharmaceutical Industries through 2026, while Edison International posts strong 2025 results and sets 2026–2027 EPS targets. Needham is bullish on Neurocrine Biosciences' pipeline, expecting growth from Crenessity and Ingrezza by 2026.